Ensign Peak Advisors Inc Raises Position in Vir Biotechnology, Inc. $VIR

Ensign Peak Advisors Inc increased its position in Vir Biotechnology, Inc. (NASDAQ:VIR) by 812.7% in the second quarter, HoldingsChannel reports. The firm owned 582,981 shares of the company’s stock after purchasing an additional 519,107 shares during the quarter. Ensign Peak Advisors Inc’s holdings in Vir Biotechnology were worth $2,938,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. PNC Financial Services Group Inc. lifted its position in Vir Biotechnology by 26.2% during the first quarter. PNC Financial Services Group Inc. now owns 10,459 shares of the company’s stock valued at $68,000 after buying an additional 2,171 shares during the period. Focus Partners Wealth increased its stake in shares of Vir Biotechnology by 15.3% in the 1st quarter. Focus Partners Wealth now owns 19,317 shares of the company’s stock worth $125,000 after acquiring an additional 2,566 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. increased its stake in shares of Vir Biotechnology by 9.1% in the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 38,290 shares of the company’s stock worth $248,000 after acquiring an additional 3,209 shares in the last quarter. State of Alaska Department of Revenue lifted its position in Vir Biotechnology by 7.7% during the 2nd quarter. State of Alaska Department of Revenue now owns 55,076 shares of the company’s stock valued at $277,000 after acquiring an additional 3,948 shares during the period. Finally, Wealth Enhancement Advisory Services LLC lifted its position in Vir Biotechnology by 33.7% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 15,993 shares of the company’s stock valued at $87,000 after acquiring an additional 4,031 shares during the period. Institutional investors own 65.32% of the company’s stock.

Insiders Place Their Bets

In related news, major shareholder Endurance (Cayman) Ltd Svf sold 235,971 shares of Vir Biotechnology stock in a transaction dated Tuesday, November 25th. The stock was sold at an average price of $6.38, for a total value of $1,505,494.98. Following the completion of the sale, the insider directly owned 14,110,209 shares in the company, valued at approximately $90,023,133.42. This trade represents a 1.64% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Vicki L. Sato sold 22,000 shares of the business’s stock in a transaction dated Monday, November 3rd. The stock was sold at an average price of $5.64, for a total value of $124,080.00. Following the completion of the transaction, the director directly owned 1,210,391 shares of the company’s stock, valued at approximately $6,826,605.24. This trade represents a 1.79% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 2,650,381 shares of company stock valued at $15,908,999. Corporate insiders own 16.00% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Vir Biotechnology in a report on Monday. Evercore ISI began coverage on Vir Biotechnology in a research report on Wednesday, September 3rd. They issued an “outperform” rating and a $12.00 price target on the stock. HC Wainwright restated a “buy” rating and issued a $15.00 price target on shares of Vir Biotechnology in a research note on Monday, September 15th. Finally, Bank of America raised Vir Biotechnology from a “neutral” rating to a “buy” rating and raised their price objective for the company from $12.00 to $14.00 in a research report on Wednesday, August 27th. Nine research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Vir Biotechnology presently has a consensus rating of “Moderate Buy” and a consensus price target of $17.30.

Vir Biotechnology Stock Performance

Shares of NASDAQ VIR opened at $6.39 on Thursday. The firm’s 50 day moving average price is $5.71 and its 200-day moving average price is $5.28. Vir Biotechnology, Inc. has a 52-week low of $4.16 and a 52-week high of $14.45. The company has a market cap of $888.98 million, a PE ratio of -1.77 and a beta of 1.27.

Vir Biotechnology (NASDAQ:VIR) last announced its quarterly earnings results on Wednesday, November 5th. The company reported ($1.17) earnings per share for the quarter, missing the consensus estimate of ($0.70) by ($0.47). The firm had revenue of $0.24 million for the quarter, compared to the consensus estimate of $1.98 million. Vir Biotechnology had a negative net margin of 2,963.54% and a negative return on equity of 50.76%. Vir Biotechnology’s revenue was up .8% on a year-over-year basis. During the same period last year, the business earned ($1.56) EPS. On average, analysts forecast that Vir Biotechnology, Inc. will post -3.92 earnings per share for the current fiscal year.

Vir Biotechnology Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).